Castle Biosciences Inc expected to post a loss of 76 cents a share - Earnings Preview

Castle Biosciences

01/11/2023 02:45

* Castle Biosciences Inc  CSTL.OQ   CSTL.O  is expected
to show a
rise in quarterly revenue when it reports  results 
    * The Friendswood Texas-based  company is expected to report
 a
31.1% increase in revenue to $48.522 million from $37.01 million
a year ago, according to the mean estimate from 8 analysts,
based on LSEG data. 
    * ​Refinitiv's mean analyst estimate for Castle Biosciences
Inc is
for a loss of 76 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 8 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Castle
Biosciences Inc is $32.5​, above​ its last closing price
of $15.62. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.91       -0.91      -0.70     Beat    23.5
 Mar. 31 2023  -0.91       -0.89      -1.10     Missed  -23.4
 Dec. 31 2022  -0.85       -0.84      -0.78     Beat    6.9​
 Sep. 30 2022  -0.92       -0.88      -0.77     Beat    12.5
 ​​Jun.        -0.77       -0.76      -0.06     Beat    92.1
 30 2022                                                
 Mar. 31 2022  -0.70       -0.71      -0.97     Missed  -37.2​
 Dec. 31 2021  -0.48       -0.47      -0.25     Beat    46.8
 Sep. 30 2021  -0.43       -0.40      -0.47     Missed  -16
 This summary was machine generated November 1 at 02:45 GMT.  All
figures in US dollars  unless otherwise stated